XML 58 R47.htm IDEA: XBRL DOCUMENT v3.26.1
REVENUE FROM CONTRACTS WITH CUSTOMERS - Narrative (Details)
$ in Thousands
 1 Months Ended 3 Months Ended 6 Months Ended 12 Months Ended
Dec. 03, 2024
USD ($)
performanceObligation
Dec. 12, 2021
USD ($)
Jul. 31, 2025
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Mar. 31, 2022
USD ($)
Jun. 30, 2026
USD ($)
Jun. 30, 2025
USD ($)
Dec. 31, 2025
USD ($)
Dec. 31, 2021
USD ($)
Disaggregation of Revenue [Line Items]                    
Total revenue       $ 0 $ 18,168   $ 367 $ 229,414    
Accounts receivable       0     0   $ 3,567  
License revenue                    
Disaggregation of Revenue [Line Items]                    
Total revenue       0 0   0 195,355    
Service revenue                    
Disaggregation of Revenue [Line Items]                    
Total revenue                 38,500  
Takeda Pharmaceuticals U.S.A., Inc. | License revenue                    
Disaggregation of Revenue [Line Items]                    
Upfront license fee $ 200,000                  
Reimbursement from limited partnership investment 51,400                  
Takeda Pharmaceuticals U.S.A., Inc. | License and Know-How                    
Disaggregation of Revenue [Line Items]                    
Upfront license fee 195,400                  
Takeda Pharmaceuticals U.S.A., Inc. | Transition Services                    
Disaggregation of Revenue [Line Items]                    
Upfront license fee $ 56,100                  
Hansoh Agreement | Hansoh Shanghai Healthtech Co Ltd                    
Disaggregation of Revenue [Line Items]                    
Total revenue   $ 18,000       $ 18,000        
Revenue, remaining performance obligation, development milestones, variable consideration       23,500     23,500      
Revenue, remaining performance obligation, sales milestones, variable consideration amount       144,000     $ 144,000      
Upfront license fee                   $ 20,000
Withholding taxes from upfront fee                   $ 2,000
License Agreement | Maximum                    
Disaggregation of Revenue [Line Items]                    
Term of the TSA fifteen                  
License Agreement | Minimum                    
Disaggregation of Revenue [Line Items]                    
Term of the TSA six                  
License Agreement | Hansoh Shanghai Healthtech Co Ltd                    
Disaggregation of Revenue [Line Items]                    
Expiration period             10 years      
License Agreement | Takeda Pharmaceuticals U.S.A., Inc.                    
Disaggregation of Revenue [Line Items]                    
Total revenue     $ 10,000       $ 1,100,000      
Expiration period             10 years      
Accounts receivable       0     $ 0   3,600  
License agreement upfront fee $ 200,000                  
Potential milestone, development based milestones       80,000     80,000      
Potential milestone payments, commercial-based milestones 280,000                  
Potential milestone payments, sales-based milestones $ 740,000                  
Number of performance obligations | performanceObligation 2                  
Tech Transfer Agreement | Manufacturing Technology Transfer Agreement                    
Disaggregation of Revenue [Line Items]                    
Service revenue       0 0   0 100    
Supply Agreement | Hansoh Shanghai Healthtech Co Ltd                    
Disaggregation of Revenue [Line Items]                    
Accounts receivable       0     0   $ 0  
Supply Agreement | Clinical Product Supply Agreement                    
Disaggregation of Revenue [Line Items]                    
Upfront license fee       $ 0 $ 0   $ 300 $ 0